Pyrazolopyridine derivative and application thereof

By developing pyrazolopyridine derivative compounds as RET inhibitors, the problem of difficult inhibition of RET proteins in the prior art is solved, effective inhibition of RET wild type and gene mutants is achieved, and excellent pharmacokinetics are provided. and high therapeutic selectivity.

CN119019423APending Publication Date: 2024-11-26GUANGZHOU BAIYUNSHAN PHARMA HLDG CO LTD BAIYUNSHAN PHARMA GENERAL FACTORY
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202310594959.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-25
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The prior art is difficult to effectively inhibit the abnormal activity of RET proteins, leading to the occurrence of a variety of cancer and intestinal disorders, and lacks effective inhibitors for RET wild-type and gene mutants.

Method used

A pyrazolopyridine derivative compound has been developed as a RET inhibitor, which has good inhibitory effect on RET wild type and gene mutants and is highly selective, suitable for a variety of administration routes, including oral administration. , parenteral, rectal and transpulmonary administration.

Benefits of technology

The compounds have excellent inhibitory effects on RET wild-type and RET gene mutants, with long half-life, good exposure, high selectivity, high bioavailability, excellent chemical and metabolic stability, reducing side effects and expanding the therapeutic index.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019423A_ABST
    Figure CN119019423A_ABST
Patent Text Reader

Abstract

The invention discloses pyrazolopyridine derivatives and application thereof, and the pyrazolopyridine derivatives are used as RET inhibitors, such as compounds as shown in formula I or pharmaceutically acceptable salts thereof. The compound has a good inhibition effect on RET wild type and RET gene mutants, and has relatively good inhibition selectivity on the RET wild type and the RET gene mutants. The compound disclosed by the invention has more excellent characteristics, for example, the compound has a good inhibition effect on RET wild type and RET gene mutants, and is longer in half-life period, better in exposure, high in selectivity, high in bioavailability and the like; in addition, the excellent properties such as chemical stability, metabolic stability, membrane permeability, solubility, and the like of the compound can promote the reduction of side effects, the enlargement of therapeutic indexes, the improvement of tolerance, and the like. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medical technology, in particular to pyrazolopyridine derivatives and applications thereof. Background Art

[0002] RET (REarranged during transfection) is a receptor tyrosine kinase (RTK) and a transmembrane glycoprotein expressed by the proto-oncogene RET located on chromosome 10. It plays a crucial role in the development of the kidney and enteric nervous system during embryonic development and is also crucial for the homeostasis of various tissues, including neurons, neuroendocrine tissues, hematopoietic tissues, and male germ cells. Unlike other RTKs, RET does not directly bind to its ligands, such as artemin, glial cell line-derived neurotrophic factor (GDNF), neurturin, and persephin, which belong to the GNDF family of ligands (GFLs). These ligands typically bind to GDNF family receptor α (GFRα). The resulting GFL-GFRα complex mediates RET self-dimerization, triggering trans-autophosphorylation of tyrosine residues on the intracellular domain, recruiting adaptor proteins, and activating a signaling cascade that promotes cell proliferation. The involved signaling pathways include MAPK, PI3K, JAK-STAT, PKA, and PKC.

[0003] There are two primary mechanisms for oncogenic activation of RET: 1. Chromosomal rearrangements generate new fusion proteins, typically fusions of the RET kinase domain with a protein containing the self-dimerization domain; 2. RET mutations directly or indirectly activate RET kinase activity. These alterations at the somatic or germline level have been implicated in the pathogenesis of various cancers. RET chromosomal rearrangements are found in 5%-10% of patients with papillary thyroid carcinoma, while RET point mutations are found in 60% of medullary thyroid carcinoma. RET fusions are found in 10-20% of all thyroid cancer patients, with CCDC6 and NCOA4 being the most common fusions. Approximately 1-2% of all NSCLC patients harbor RET fusion proteins, with KIF5B-RET being the most common.

[0004] In summary, abnormal RET expression or activation has been found in a variety of tumors and gastrointestinal disorders such as irritable bowel syndrome. Therefore, RET inhibitors have potential clinical value in tumors or intestinal disorders. Summary of the Invention

[0005] The present invention aims to address at least one of the aforementioned technical problems in the prior art. To this end, the present invention provides a pyrazolopyridine derivative as a RET inhibitor and its use, wherein the compound exhibits a potent inhibitory effect against wild-type RET and RET gene mutants, and exhibits good inhibitory selectivity against both wild-type and mutant RET.

[0006] In order to achieve the above object, the technical solution adopted by the present invention is:

[0007] The first aspect of the present invention provides a compound represented by Formula I or a pharmaceutically acceptable salt thereof:

[0008]

[0009] in,

[0010] T1 is selected from -CH2-, -C(=O)-C 1-3 Alkyl- and -C(=O)-, the -CH2- and -C(=O)-C 1-3 Alkyl - optionally substituted with 1 or 2 R2;

[0011] T2 is selected from C or N;

[0012] X is selected from O, NH or -N(CH)3-;

[0013] R1 is independently selected from H, CF3, F, Cl, Br, I, OH, NH2, CN, C 1-3 Alkyl and C 1-3 Alkoxy, the C 1-3 Alkoxy and C 1-3 Alkoxy is optionally substituted with 1, 2 or 3 R3;

[0014] R2 are independently selected from H, F, Cl, Br, I, OH and CH3;

[0015] R3 are independently selected from H, F, Cl, Br and I;

[0016] n is 1, 2, or 3.

[0017] In some embodiments of the present invention, in the compound represented by Formula I or a pharmaceutically acceptable salt thereof,

[0018] T1 is selected from -CH2- and -C(=O)-, wherein -CH2- is substituted by 1 or 2 R2;

[0019] T2 is selected from C or N;

[0020] X is selected from O or -N(CH)3-;

[0021] R1 is independently selected from H, CF3, OH, NH2, C 1-3 Alkyl and C 1-3 Alkoxy, the C 1-3 Alkoxy and C 1-3 Alkoxy is optionally substituted with 1, 2 or 3 R3;

[0022] R2 are independently selected from H, F, Cl, Br, I, OH and CH3;

[0023] R3 are independently selected from H, F, Cl, Br and I;

[0024] n is 1, 2, or 3.

[0025] In some embodiments of the present invention, in the compound represented by Formula I or a pharmaceutically acceptable salt thereof,

[0026] T1 is selected from -CH2- and -C(=O)-, wherein -CH2- is substituted by 1 or 2 R2;

[0027] T2 is selected from C or N;

[0028] X is selected from O or NH;

[0029] R1 is independently selected from H, CF3, OH and C 1-3 Alkoxy, the C 1-3 Alkoxy is optionally substituted with 1, 2 or 3 R3;

[0030] R2 are independently selected from H, F, Cl, Br, I, OH and CH3;

[0031] R3 are independently selected from H, F, Cl, Br and I;

[0032] n is 1 or 2.

[0033] In some embodiments of the present invention, in the compound represented by Formula I or a pharmaceutically acceptable salt thereof,

[0034] T1 is -C(=O)-;

[0035] T2 is selected from C or N;

[0036] X is selected from O, NH or -N(CH)3-;

[0037] R1 is independently selected from H, CF3, F, Cl, Br, I, OH, NH2, CN, C 1-3 Alkyl and C 1-3 Alkoxy, the C 1-3 Alkoxy and C 1-3 Alkoxy is optionally substituted with 1, 2 or 3 R3;

[0038] R2 are independently selected from H, F, Cl, Br, I, OH and CH3;

[0039] R3 are independently selected from H, F, Cl, Br and I;

[0040] n is 1, 2, or 3.

[0041] In some embodiments of the present invention, in the compound represented by Formula I or a pharmaceutically acceptable salt thereof,

[0042] T1 is -CH2-, wherein the -CH2- is optionally substituted by 1 or 2 R2;

[0043] T2 is selected from C or N;

[0044] X is selected from O, NH or -N(CH)3-;

[0045] R1 is independently selected from H, CF3, F, Cl, Br, I, OH, NH2, CN, C 1-3 Alkyl and C 1-3 Alkoxy, the C 1-3 Alkoxy and C 1-3 Alkoxy is optionally substituted with 1, 2 or 3 R3;

[0046] R2 are independently selected from H, F, Cl, Br, I, OH and CH3;

[0047] R3 are independently selected from H, F, Cl, Br and I;

[0048] n is 1, 2, or 3.

[0049] In some embodiments of the present invention, the compound represented by formula I is selected from:

[0050]

[0051]

[0052] The second aspect of the present invention provides a pharmaceutical composition comprising the compound of Formula I or a pharmaceutically acceptable salt thereof, and pharmaceutically acceptable excipients.

[0053] In some embodiments of the present invention, the pharmaceutical compositions of the present invention are suitable for a variety of routes of administration and can be formulated into any pharmaceutically acceptable dosage form. For example, the pharmaceutical compositions can be administered to patients or subjects requiring such treatment via oral, parenteral, rectal, or transpulmonary administration. For oral administration, the pharmaceutical compositions can be formulated into oral preparations, such as conventional oral solid preparations such as tablets, capsules, pills, granules, or oral liquid preparations such as oral solutions, oral suspensions, and syrups. Suitable fillers, binders, disintegrants, lubricants, and the like can be added to these oral preparations. For parenteral administration, the pharmaceutical compositions can also be formulated into injectable preparations, including injection solutions, sterile powders for injection, and concentrated solutions for injection. Injectable preparations can be produced using conventional methods in the pharmaceutical field. Additives may be omitted or added depending on the properties of the drug. For rectal administration, the pharmaceutical compositions can be formulated into suppositories. For transpulmonary administration, the pharmaceutical compositions can be formulated into inhalation preparations, aerosols, powder sprays, or sprays.

[0054] In some embodiments of the present invention, pharmaceutically acceptable excipients refer to substances that are non-toxic, compatible with the active ingredient and otherwise biologically applicable to organisms. The selection of specific excipients will depend on the mode of administration or disease type and state for treating a particular patient. Examples of pharmaceutically acceptable excipients include, but are not limited to, solvents, diluents, dispersants, suspending agents, surfactants, isotonic agents, thickeners, emulsifiers, adhesives, lubricants, stabilizers, hydrating agents, emulsification accelerators, buffers, absorbents, colorants, ion exchangers, release agents, coatings, flavoring agents, and antioxidants, etc., which are conventional in the pharmaceutical field. If necessary, flavoring agents, preservatives, and sweeteners, etc. can also be added to the pharmaceutical composition.

[0055] The third aspect of the present invention provides a use of the compound of Formula I or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition in the preparation of kinase inhibitor drugs.

[0056] In some embodiments of the present invention, the kinase inhibitor drug is a RET kinase inhibitor drug.

[0057] The fourth aspect of the present invention provides a use of the compound of Formula I or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition, in the preparation of a drug for treating or preventing diseases related to abnormal RET kinase activity.

[0058] In some embodiments of the present invention, the related diseases caused by abnormal RET kinase activity include at least one of cancer, irritable bowel syndrome and / or pain associated with irritable bowel syndrome.

[0059] In some embodiments of the present invention, the cancer includes at least one of papillary thyroid cancer, medullary thyroid cancer, pheochromocytoma, pancreatic cancer, multiple endocrine neoplasia, breast cancer, testicular cancer, small cell lung cancer, non-small cell lung cancer, blood tumors, colorectal cancer, ovarian cancer, cervical cancer, gastric cancer, prostate cancer, and salivary gland cancer.

[0060] definition

[0061] Unless otherwise stated, the initial definitions provided for groups or terms in the present invention apply to the groups or terms throughout the specification; for terms that are not specifically defined in the present invention, they should be given the meanings that those skilled in the art can give them based on the disclosure and context.

[0062] "Substitution" means that a hydrogen atom in a molecule is replaced by another different atom or group.

[0063] The minimum and maximum carbon atom content in a hydrocarbon group is indicated by a prefix, for example, the prefix C a~b Alkyl refers to any alkyl group containing from "a" to "b" carbon atoms. Thus, for example, "C 1~4 "Alkyl" refers to an alkyl group containing 1 to 4 carbon atoms.

[0064] The term "pharmaceutically acceptable" means chemically and physically compatible with the other ingredients that make up a pharmaceutical dosage form and physiologically compatible with the receptors.

[0065] The term "salt" refers to the acid salt formed with inorganic acid and / or organic acid of the above-mentioned compound or its stereoisomer, or the basic salt formed with alkali, also including zwitterionic salts (inner salts), and also including quaternary ammonium salts, such as alkylammonium salts. These salts can be obtained by separation and purification during the preparation of the compound, or can be obtained by mixing the above-mentioned compound or its stereoisomer with a certain amount of acid or alkali appropriately (e.g., equivalent). These salts may be collected by forming a precipitate in the solution by filtration, or recovered after solvent evaporation, or obtained by freeze-drying after reaction in an aqueous medium. The salt described in the present invention can be the hydrochloride, sulfate, citrate, benzenesulfonate, hydrobromide, hydrofluoride, phosphate, acetate, propionate, succinate, oxalate, malate, succinate, fumarate, maleate, tartrate or trifluoroacetate of the compound.

[0066] The compounds provided in the present invention can be named according to the IUPAC (International Union of Pure and Applied Chemistry) or CAS (Chemical Abstracts Service, CoLumbus, OH) nomenclature system.

[0067] In certain embodiments, one or more compounds of the present invention may be used in combination with one another. Compounds of the present invention may also be used in combination with any other active agent to prepare a drug or pharmaceutical composition for regulating cell function or treating a disease. If a group of compounds is used, these compounds may be administered to a subject simultaneously, separately, or sequentially.

[0068] In the present invention, "M" refers to mol / L; "mM" refers to mmol / L; and "μM" refers to μmol / L.

[0069] The "room temperature" in the present invention refers to 25±5°C.

[0070] The beneficial effects of the present invention are:

[0071] The compounds of the present invention possess many excellent properties, such as good inhibitory effects on RET wild-type and RET gene mutants, longer half-life, better exposure, high selectivity, high bioavailability, etc.; in addition, the excellent properties of the compounds, such as chemical stability, metabolic stability, membrane permeability, solubility, etc., can promote the reduction of side effects, the expansion of therapeutic index or the improvement of tolerance. DETAILED DESCRIPTION

[0072] The present invention is further described in detail below using specific examples. Unless otherwise specified, the raw materials, reagents, and apparatus used in the examples and comparative examples are available from conventional commercial sources or by conventional methods. Unless otherwise specified, all experimental or testing methods are conventional in the art.

[0073] The raw materials and equipment used in the specific embodiments of the present invention are all known products and are obtained by purchasing commercial products.

[0074] NMR measurements were performed using a Bruker Avance III 400 NMR spectrometer. The NMR shift (δ) was measured at 10 -6 The solvent was deuterated dimethyl sulfoxide (DMSO-d6) and the internal standard was tetramethylsilane (TMS).

[0075] The known starting materials, reagents and solvents of the present invention can be synthesized by methods known in the art, or can be purchased from Shanghai Aladdin Biochemical Technology Co., Ltd., Shanghai Bid Pharmaceutical Technology Co., Ltd. and Shanghai Titan Technology Co., Ltd.

[0076] In the following examples, the following abbreviations have the following meanings. If an abbreviation is not defined, it has the generally accepted meaning. Dioxane is 1,4-dioxane; DCM is dichloromethane; 2,6-lutidine refers to 2,6-lutidine; TMSOTf is trimethylsilyl trifluoromethanesulfonate; and PCC is pyridinium chlorochromate.

[0077] Example 1

[0078] In this example, 6-(2,5-dihydrofuran-3-yl)-4-(5-(6-((6-hydroxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane-3-yl)pyrazin-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (Compound 1) was prepared. The specific process was as follows:

[0079] Reaction route:

[0080]

[0081] Step A: Preparation of tert-butyl 3-(5-(6-bromo-3-cyanopyrazolo[1,5-a]pyridin-4-yl)pyrazin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate (Compound 1c):

[0082] Compound 1a (30.5 g, 75.8 mmol, 1.0 eq) and compound 1b (26.6 g, 72.0 mmol, 0.95 eq) were dissolved in dioxane (250 mL). Potassium phosphate (32.3 g, 152 mmol, 2.0 eq) and Pd(dppf)Cl2·DCM (6.14 g, 7.58 mmol, 0.1 eq) were added. The mixture was heated to 90°C under nitrogen for 2 hours. LCMS showed the disappearance of the starting material and the main peak was the target molecular weight. Heating was stopped, the reaction mixture was cooled to room temperature, filtered, and the filtrate was concentrated to dryness. Purification by medium-pressure preparative chromatography afforded compound 1c (22.9 g, 61%) as an off-white solid.

[0083] LCMS (ESI) m / z: [M+H] + =496.13.

[0084] Step B: Preparation of tert-butyl 3-(5-(3-cyano-6-(2,5-dihydrofuran-3-yl)pyrazolo[1,5-a]pyridin-4-yl)pyrazin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate (Compound 1e):

[0085] Compound 1c (0.80 g, 1.61 mmol, 1.0 eq) and compound 1d (0.38 g, 1.93 mmol, 1.2 eq) were dissolved in dioxane (10 mL). Potassium phosphate (0.68 g, 3.22 mmol, 2.0 eq) and Pd(dppf)Cl2·DCM (0.13 g, 0.16 mmol, 0.1 eq) were added. The mixture was heated to 90°C under nitrogen for 3 hours. LCMS showed the disappearance of the starting material and the main peak was the target molecular weight. Heating was stopped, the reaction mixture was cooled to room temperature, filtered, and the filtrate was concentrated to dryness. Purification by medium-pressure preparative chromatography afforded compound 1e (0.61 g, 78%) as an off-white solid.

[0086] LCMS (ESI) m / z: [M+H] + =486.19.

[0087] Step C: Preparation of 4-(5-(3,6-diazabicyclo[3.1.1]heptane-3-yl)pyrazin-2-yl)-6-(2,5-dihydrofuran-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (Compound 1f):

[0088] Compound 1e (0.59 g, 1.22 mmol, 1.0 eq) was dissolved in DCM (5 mL), followed by the addition of 2,6-lutidine (0.20 g, 1.83 mmol, 1.5 eq). The temperature was lowered to 0°C, and TMSOTf (0.33 g, 1.46 mmol, 1.2 eq) was added and allowed to react for 4 hours. LCMS showed the disappearance of the starting material, with the main peak representing the target molecular weight. The reaction was quenched by the addition of water (0.1 mL), allowed to warm to room temperature, filtered, and the filter cake washed with water. The mixture was dried under vacuum at 40°C to afford Compound 1f (0.62 g, 95%) as a yellow solid.

[0089] LCMS (ESI) m / z: [M+H] + =386.18.

[0090] Step D: Preparation of 6-(2,5-dihydrofuran-3-yl)-4-(5-(6-((6-hydroxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane-3-yl)pyrazin-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (Compound 1):

[0091] Compound 1f (0.60 g, 1.12 mmol, 1.0 eq) was dissolved in DCM (5 mL), followed by the addition of compound 1g (0.21 g, 1.68 mmol, 1.5 eq) and triethylamine (0.12 g, 1.23 mmol, 1.1 eq). After reacting at room temperature for 3 hours, NaBH(OAc)3 (0.36 g, 1.68 mmol, 1.5 eq) was added and the reaction continued for 20 hours. LCMS showed the disappearance of the starting material, with the main peak representing the target molecular weight. The reaction solution was diluted with DCM (20 mL) and then washed sequentially with saturated aqueous sodium bicarbonate solution (15 mL) and water (15 mL). The organic phase was collected, concentrated to dryness, and purified by medium-pressure preparative chromatography to afford compound 1 (0.27 g, 49%) as a brown solid.

[0092] LCMS (ESI) m / z: [M+H] + =492.24;

[0093] 1 H NMR(400MHz,DMSO-d6)δ8.86(d,J=0.9Hz,1H),8.70(d,J=1.3Hz,1H),8.67(s,1H),8 .31(d,J=1.9Hz,1H),8.29(d,J=1.2Hz,1H),7.96(d,J=1.4Hz,1H),7.41(d,J=8.6,2 .5Hz,1H),6.72(m,1H),6.26(d,J=8.4Hz,1H),4.47(m,2H),4.40(s,2H),3.81(m,2H ), 3.69 (d, J = 5.8Hz, 2H), 3.62 (d, J = 12.3Hz, 2H), 3.30 (s, 2H), 1.62 (d, J = 8.5Hz, 1H).

[0094] Example 2

[0095] This example prepared 6-(3,6-dihydro-2H-pyran-4-yl)-4-(5-(6-((6-hydroxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane-3-yl)pyrazin-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (Compound 2)

[0096] The preparation of compound 2 can refer to the route and similar method steps of the aforementioned Preparation Example 1, except that the raw material used in step B is 3,6-dihydro-2H-pyran-4-boronic acid pinacol ester. The specific data are shown in Table 1.

[0097] Table 1

[0098]

[0099]

[0100] Example 3

[0101] This example prepared 4-(6-(6-((6-hydroxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane-3-yl)pyrazin-2-yl)-6-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (Compound 3)

[0102] The preparation of compound 3 can refer to the route and similar method steps of the aforementioned Preparation Example 1, except that the raw material used in step B is 1-methyl-1,2,3,6-tetrahydropyridine-4-boronic acid pinacol ester. The specific data are shown in Table 2.

[0103] Table 2

[0104]

[0105] Example 4

[0106] This example prepared 6-(3,6-dihydro-2H-pyran-4-yl)-4-(5-(6-((5-hydroxypyrazin-2-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane-3-yl)pyrazin-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (Compound 4)

[0107] The preparation of compound 4 can refer to the route and similar method steps of the aforementioned Preparation Example 1, except that the raw material used in step D is 5-hydroxypyrazine-2-carboxaldehyde. Specific data are shown in Table 3.

[0108] Table 3

[0109]

[0110] Example 5:

[0111] This example prepared 4-(5-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane-3-yl)pyrazin-2-yl)-6-(5-oxo-2,5-dihydrofuran-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (Compound 5)

[0112] Reaction route:

[0113]

[0114] Step A: Preparation of tert-butyl 3-(5-(3-cyano-6-(2,5-dihydrofuran-3-yl)pyrazolo[1,5-a]pyridin-4-yl)pyrazin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate (Compound 1e)

[0115] The same as step B of the above-mentioned preparation example 1.

[0116] Step B: Preparation of tert-butyl 3-(5-(3-cyano-6-(5-oxo-2,5-dihydrofuran-3-yl)pyrazolo[1,5-a]pyridin-4-yl)pyrazin-2-yl)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate (Compound 5a)

[0117] PCC (2.13 g, 9.88 mmol, 2.0 eq) was dissolved in DCM (20 mL). Compound 1e (1.0 M in dichloromethane, 2.40 g, 4.94 mmol, 1.0 eq) was added under nitrogen and allowed to react at room temperature for 4 hours. LCMS showed the disappearance of the starting material and the appearance of the target compound. The reaction mixture was diluted with ether (20 mL) and filtered through a pad of Celite. The filter cake was washed three times with ether (5 mL). The filtrate was concentrated to dryness and purified by medium-pressure preparative chromatography to afford Compound 5a (0.39 g, 16%) as a yellow solid.

[0118] LCMS (ESI) m / z: [M+H] + =500.18.

[0119] Step C: Preparation of 4-(5-(3,6-diazabicyclo[3.1.1]heptane-3-yl)pyrazin-2-yl)-6-(5-oxo-2,5-dihydrofuran-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (Compound 5b)

[0120] Compound 5a (0.37 g, 0.74 mmol, 1.0 eq) was dissolved in DCM (5 mL), followed by the addition of 2,6-lutidine (0.12 g, 1.11 mmol, 1.5 eq). The temperature was lowered to 0°C, and TMSOTf (0.20 g, 0.89 mmol, 1.2 eq) was added and allowed to react for 4 hours. LCMS showed the disappearance of the starting material, with the main peak representing the target molecular weight. The reaction was quenched by the addition of water (0.1 mL), allowed to warm to room temperature, filtered, and the filter cake washed with water. The product was dried under vacuum at 40°C to afford Compound 5b (0.37 g, 91%) as a yellow solid.

[0121] LCMS (ESI) m / z: [M+H] + =386.18.

[0122] Step D: Preparation of 4-(5-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane-3-yl)pyrazin-2-yl)-6-(5-oxo-2,5-dihydrofuran-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (Compound 5)

[0123] Compound 5b (0.35 g, 0.64 mmol, 1.0 eq) was dissolved in DCM (5 mL), followed by the addition of compound 5c (0.13 g, 0.96 mmol, 1.5 eq) and triethylamine (0.07 g, 0.70 mmol, 1.1 eq). After reacting at room temperature for 3 hours, NaBH(OAc)3 (0.20 g, 0.96 mmol, 1.5 eq) was added and the reaction continued for 20 hours. LCMS showed the disappearance of the starting material, with the main peak representing the target molecular weight. The reaction solution was diluted with DCM (20 mL) and then washed sequentially with saturated aqueous sodium bicarbonate solution (15 mL) and water (15 mL). The organic phase was collected, concentrated to dryness, and purified by medium-pressure preparative chromatography to afford compound 5 (0.13 g, 40%) as a yellow solid.

[0124] LCMS (ESI) m / z: [M+H] + =521.25;

[0125] 1 H NMR(400MHz,DMSO-d6)δ9.29(d,J=1.1Hz,1H),8.80(d,J=1.1Hz,1H),8.78(s,1H),8.29 (d,J=1.3Hz,1H),8.17(d,J=1.4Hz,1H),8.09(d,J=2.0Hz,1H),7.69(d,J=8.5,2.6Hz,1 H),7.21(s,1H),6.77(d,J=8.5Hz,1H),5.01(s,2H),3.82(m,3H),3.81(m,2H),3.69(d, J=5.6Hz,2H),3.64(d,J=12.4Hz,2H),3.51(s,2H),2.55(m,1H),1.63(d,J=8.6Hz,1H).

[0126] Example 6:

[0127] This example prepared 4-(5-(6-((6-methoxypyridin-3-yl)methyl)-diazabicyclo[3.1.1]heptane-3-yl)pyrazin-2-yl)-6-(6-oxo-3,6-dihydro-2H-pyran-4-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (Compound 6)

[0128] The preparation of compound 6 can refer to the route and similar method steps of the aforementioned Preparation Example 5, except that the raw material used in step A is 3,6-dihydro-2H-pyran-4-boronic acid pinacol ester. The specific data are shown in Table 4.

[0129] Table 4

[0130]

[0131]

[0132] Example 7

[0133] This example prepared 6-(6-oxo-3,6-dihydro-2H-pyran-4-yl)-4-(5-(6-((6-(trifluoromethyl)pyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane-3-yl)pyrazin-2-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (Compound 7)

[0134] The preparation of compound 7 can be carried out according to the route and similar method steps of the aforementioned Preparation Example 5, except that the raw material used in step A is 3,6-dihydro-2H-pyran-4-boronic acid pinacol ester, and the raw material used in step D is 6-(trifluoromethyl)pyridinecarboxaldehyde. Specific data are shown in Table 5.

[0135] Table 5

[0136]

[0137] Example 8:

[0138] This example prepared 4-(5-(6-((5-methoxypyrazin-2-yl)methyl)-3,6-diazabicyclo[3.1.1]heptane-3-yl)pyrazin-2-yl)-6-(6-oxo-3,6-dihydro-2H-pyran-4-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (Compound 8)

[0139] The preparation of compound 8 can be carried out according to the route and similar method steps of the aforementioned Preparation Example 5, except that the raw material used in step D is 5-methoxypyrazine-2-carboxaldehyde. The specific data are shown in Table 6.

[0140] Table 6

[0141]

[0142] Test Example 1

[0143] This test example tests the inhibitory activity of the compound on kinases. The specific process is as follows:

[0144] (1) Experimental purpose

[0145] The enzyme activity was detected by Z′-LYTETM kinase assay, and the IC50 value of the compound was used as an indicator to evaluate the inhibitory effect of the compound on RET, RET(V804M) and RET(V804L) kinases.

[0146] (2) Experimental methods

[0147] The compounds used in the assays for RET, RET(V804M) and RET(V804L) kinases were diluted 3-fold to obtain 10 concentrations ranging from 3 μM to 0.152 nM. The content of DMSO in the assay reactions was 1%.

[0148] (3) Reagents

[0149] Basic reaction buffer, 20 mM hydroxyethylpiperazine ethanesulfonic acid (Hepes) (pH 7.5) buffer, 10 mM MgCl2, 1 mM ethylene glycol bisaminoethyl ether tetraacetic acid (EGTA), 0.02% polyoxyethylene lauryl ether (Brij35), 0.02 mg / mL bovine serum albumin, 0.1 mM Na3VO4, 2 mM dithiothreitol (DTT), 1% DMSO.

[0150] (4) Compounds

[0151] The test compound was dissolved in 100% DMSO and diluted to 10 mM for use. The solution was diluted using Integra Viaflo Assist.

[0152] (5) Reaction process of universal enzymes

[0153] Test conditions: RET enzyme concentration is 3 μM, peptide substrate CHKtide concentration is 1000 μM, ATP concentration is 20 μM; RET(V804M) and RET(V804L) enzyme concentration is 80 μM, substrate peptide concentration is 1000 μM, ATP concentration is 30 μM.

[0154] Reaction procedure: Prepare kinase / peptide solutions according to test conditions. Add compound solutions at varying concentrations and incubate at room temperature for 20 minutes. Add corresponding concentrations of 33P-ATP and incubate at room temperature for 120 minutes. Radioactivity is detected by filter-binding.

[0155] (6) Reaction detection

[0156] The reaction was terminated by adding 0.5% phosphoric acid to the kinase reaction solution and the plate was read using an Envision instrument.

[0157] (7) Data Analysis

[0158] The data were converted into phosphorylation rate and inhibition rate, and parameter curve fitting (GraphPad Software) was performed to obtain compound IC50 data (nM). The experimental results are shown in Table 7:

[0159] Table 7 Kinase activity IC50 test results of the compounds of the present invention

[0160] Example RET RET V804M RET V804L 1 +++ ++ ++ 2 +++ +++ +++ 3 +++ ++ ++ 4 +++ +++ +++ 5 +++ ++ ++ 6 +++ +++ +++ 7 +++ + + 8 +++ ++ ++

[0161] Note: “+” indicates that the IC50 value is greater than 100 nM; “++” indicates that the IC50 value is less than or equal to 100 nM and greater than 10 nM; “+++” indicates that the IC50 value is less than or equal to 10 nM.

[0162] Experimental conclusion: The compound of the present invention has excellent inhibitory activity against RET and its mutant forms RET V804M and RET V804L kinases, and will have excellent therapeutic effects in patients with RET-abnormal tumors.

[0163] Test Example 2

[0164] This test example tests the inhibitory effect of the compound on tumors. The specific process is as follows:

[0165] (1) Experimental purpose

[0166] The CTG method was used to test the 50% inhibitory concentration (IC50) of the compounds in a series of tumor cells.

[0167] (2) The experimental reagents and test samples used are as follows

[0168] CellTiter-Glo (CTG), RPMI medium, FBS (fetal bovine serum), DMSO, double-antibody, 96-well cell culture plate (white wall and opaque bottom), BA / F3, BA / F3-KIF5B-RET (stable cell line)

[0169] (3) Experimental steps

[0170] Cell Plating: Harvest BA / F3 and BA / F3-KIF5B-RET cells in the exponential growth phase and count viable cells using a Vi-Cell XR cell counter. Adjust the cell suspension to the appropriate concentration using RPMI complete medium (89% RPMI + 10% FBS + 1% double-antibody). Add 90 μL of cell suspension to each well of a 96-well cell culture plate, achieving a final cell concentration of 2000 cells / well and 100 cells / well, respectively.

[0171] Drug Treatment: Dissolve each test compound in DMSO to a final concentration of 10 mM stock solution. Prepare a 3X serial dilution series using the stock solution and RPMI complete medium (89% RPMI + 10% FBS + 1% double-antibody), for a total of 10 working concentrations. Each solution has a final DMSO concentration of 0.1%. After overnight incubation of cells, add 10 μL of each working solution corresponding to the 10-step dilution series. Incubate in a 37°C, 5% CO2 incubator for 72 hours. A negative control without compound addition was also established.

[0172] Plate reader assay: 72 hours after drug treatment, add 50 μL (1 / 2 the culture volume) of pre-thawed and room temperature CTG solution to each well according to the CTG operating instructions. Mix on a microplate shaker for 2 minutes. After incubation at room temperature for 10 minutes, measure the fluorescence signal using a multi-function microplate reader.

[0173] Data Analysis: Cell viability was calculated using the formula Vsample / Vvehicle control x 100%, where Vsample represents the reading of the drug-treated group and Vvehicle control represents the mean value of the vehicle control group. GraphPadPrism 5.0 software was used to construct sigmoidal dose-viability curves using a nonlinear regression model and calculate IC50 values ​​(nM). The results are shown in Table 8:

[0174] Table 8 IC50 test results of the compounds of the present invention against RET mutant cell lines

[0175] Example BA / F3-KIF5B-RET 1 +++ 2 +++ 4 +++ 5 +++ 6 +++

[0176] Note: “+” indicates that the IC50 value is greater than 500 nM; “++” indicates that the IC50 value is less than or equal to 500 nM and greater than 100 nM; “+++” indicates that the IC50 value is less than or equal to 100 nM.

[0177] Experimental conclusion: The compound of the present invention has a good inhibitory effect on the growth of RET mutant cells and can be effectively used in the treatment of diseases related to abnormal RET activity.

[0178] Test Example 3

[0179] This test example tests the pharmacokinetic characteristics of the compound. The specific process is as follows:

[0180] (1) Experimental purpose

[0181] The pharmacokinetic characteristics of the test compounds in mice.

[0182] (2) Experimental process

[0183] A clear solution of the test compound at 0.1 mg / mL in 10% PEG400 (polyethylene glycol 400) + 90% (10% hydroxypropyl-β-cyclodextrin) was injected into female Balb / c mice (7-9 weeks old) overnight fasted via the tail vein at a dose of 0.2 mg / kg. Approximately 30 μL of blood was collected from the jugular or tail vein at 0.0833 h, 0.25 h, 0.5 h, 1.0 h, 2.0 h, 4.0 h, 8.0 h, and 24 h after intravenous administration. The test compound was suspended in the vehicle at 0.2 mg / mL and administered orally to female Balb / c mice (7-9 weeks old) overnight fasted at a dose of 2 mg / kg. Approximately 30 μL of blood was collected from the jugular or tail vein of female Balb / c mice at 0.0833 h, 0.25 h, 0.5 h, 1.0 h, 2.0 h, 4.0 h, 6.0 h, 8.0 h, and 24 h after oral administration. The blood was placed in an EDTA-K2-containing anticoagulant tube and centrifuged to separate the plasma. Plasma concentrations were determined by LC-MS / MS, and relevant pharmacokinetic parameters were calculated using the non-compartmental linear logarithmic trapezoidal method using WinNonlin™ Version 6.3 (Pharsight, Mountain View, CA) pharmacokinetic software. The results are shown in Table 9:

[0184] Table 9 Pharmacokinetic results of the compounds of the present invention in mice

[0185]

[0186] Note: Elimination half-life (T 1 / 2 ), the area under the plasma concentration curve from point 0 to the last quantifiable time point (AUC 0-last ), bioavailability (F), peak concentration (C max ), peak time (T max ).

[0187] Experimental conclusion: The compounds of the present invention exhibited a faster time to peak activity, a longer half-life, good drug exposure, and excellent oral bioavailability. In short, this series of compounds has good pharmacokinetic properties.

[0188] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be considered as equivalent replacement methods and are included in the scope of protection of the present invention.

Claims

1. Pyrazolopyridine derivatives and their use, compounds represented by formula I or pharmaceutically acceptable salts thereof: in, T1 is selected from -CH2-, -C(=O)-C 1-3 Alkyl- and -C(=O)-, the -CH2- and -C(=O)-C 1-3 Alkyl - optionally substituted with 1 or 2 R2; T2 is selected from C or N; X is selected from O, NH or -N(CH)3-; R1 is independently selected from H, CF3, F, Cl, Br, I, OH, NH2, CN, C 1-3 Alkyl and C 1-3 Alkoxy, the C 1-3 Alkoxy and C 1-3 The alkoxy group is optionally substituted with 1, 2 or 3 R3; R2 is independently selected from H, F, Cl, Br, I, OH and CH3; R3 are independently selected from H, F, Cl, Br and I; n is 1, 2, or 3.

2. The compound of formula I or a pharmaceutically acceptable salt thereof according to claim 1, characterized in that: In the compound represented by formula I or a pharmaceutically acceptable salt thereof, T1 is selected from -CH2- and -C(=O)-, wherein -CH2- is substituted by 1 or 2 R2; T2 is selected from C or N; X is selected from O or -N(CH)3-; R1 is independently selected from H, CF3, OH, NH2, C 1-3 Alkyl and C 1-3 Alkoxy, the C 1-3 Alkoxy and C 1-3 The alkoxy group is optionally substituted with 1, 2 or 3 R3; R2 is independently selected from H, F, Cl, Br, I, OH and CH3; R3 are independently selected from H, F, Cl, Br and I; n is 1, 2, or 3.

3. The compound of formula I or a pharmaceutically acceptable salt thereof according to claim 1, characterized in that: In the compound represented by formula I or a pharmaceutically acceptable salt thereof, T1 is selected from -CH2- and -C(=O)-, wherein -CH2- is substituted by 1 or 2 R2; T2 is selected from C or N; X is selected from O or NH; R1 is independently selected from H, CF3, OH and C 1-3 Alkoxy, the C 1-3 The alkoxy group is optionally substituted with 1, 2 or 3 R3; R2 is independently selected from H, F, Cl, Br, I, OH and CH3; R3 are independently selected from H, F, Cl, Br and I; n is 1 or 2.

4. The compound of formula I or a pharmaceutically acceptable salt thereof according to claim 1, characterized in that: The compound represented by formula I is selected from:

5. A pharmaceutical composition, characterized in that: It comprises the compound represented by formula I as claimed in any one of claims 1 to 4 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

6. Use of the compound of formula I or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4, or the pharmaceutical composition according to claim 5, in the preparation of kinase inhibitor drugs.

7. The use according to claim 6, characterized in that: The kinase inhibitor drug is a RET kinase inhibitor drug.

8. Use of a compound of formula I or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 4, or a pharmaceutical composition as claimed in claim 5, in the preparation of a medicament for treating or preventing diseases related to abnormal RET kinase activity.

9. The use according to claim 8, characterized in that: The related diseases caused by abnormal RET kinase activity include at least one of cancer, irritable bowel syndrome and / or pain associated with irritable bowel syndrome.

10. The use according to claim 9, characterized in that: The cancer includes at least one of papillary thyroid cancer, medullary thyroid cancer, pheochromocytoma, pancreatic cancer, multiple endocrine neoplasia, breast cancer, testicular cancer, small cell lung cancer, non-small cell lung cancer, blood tumors, colorectal cancer, ovarian cancer, cervical cancer, gastric cancer, prostate cancer, and salivary gland cancer.

Citation Information

Cited By

  • Application of pyrazolopyridine compound as FGFR inhibitor

    CN122624484A